Rafferty Asset Management’s Sutro Biopharma STRO Stock Holding History

Rafferty Asset Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,573	Closed	-$997K	–	1142
2023 Q1	$997K	Buy	21,573 +11,709	+119%	+$743K	0.01%	800
2022 Q4	$797K	Buy	+9,864	New	+$686K	0.01%	807
2022 Q2	–	Sell	-16,479	Closed	-$1.35M	–	1220
2022 Q1	$1.35M	Buy	16,479 +8,366	+103%	+$796K	0.01%	714
2021 Q4	$1.21M	Buy	8,113 +2,542	+46%	+$455K	0.01%	797
2021 Q3	$1.05M	Sell	5,571 -3,246	-37%	-$617K	0.01%	802
2021 Q2	$1.64M	Sell	8,817 -4,913	-36%	-$962K	0.01%	740
2021 Q1	$3.13M	Buy	+13,730	New	+$3.26M	0.02%	460

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Rafferty Asset Management's STRO Position: Q2 2023 in Review

Rafferty Asset Management sold out of Sutro Biopharma (STRO) in Q2 2023, closing a stake of 21,573 shares — an estimated $997K sold.

Rafferty Asset Management first reported a position in STRO in Q1 2021 and held it in 7 quarters. The position peaked at $3.13M in Q1 2021. 120 funds tracked by Wall St. Rank hold STRO as of Q2 2023.

Rafferty Asset Management reported no remaining Sutro Biopharma position as of Q2 2023 after selling out during the quarter.
Rafferty Asset Management sold 21,573 Sutro Biopharma shares in Q2 2023, an estimated $997K.
Rafferty Asset Management first reported a position in Sutro Biopharma in Q1 2021 and held it in 7 quarters.
Rafferty Asset Management's Sutro Biopharma position peaked at $3.13M in Q1 2021.
120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.